INDIANAPOLIS--(BUSINESS WIRE)--Esanex, Inc., a clinical stage company developing Heat Shock Protein inhibitors for the treatment of cancer, today announced that it is presenting preclinical data from ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback